Uddrag fra finanshuse:
| Is that an AI stock? |
| Another day another new all time high for Eli Lilly. |
 Refinitiv |
| Obesity is the new AI |
| Time to track who is talking obesity on the earnings calls. Chart shows S&P 500 HC companies who have referred to Obesity / GLP-1 during their 2Q23 earnings calls. |
 Goldman |
| COVID vaccines are so 2022 |
| A long LLY/short PFE setup has generated ~90% returns YTD and the gap between these two stocks is continuing to widen … |
 FactSet |
| Disruption wedge |
| GLP-1 disruption wedge still growing: Performance of the GS HC Obesity Basket vs the GS HC GLP-1 risk basket is pretty extreme. |
 Goldman |
| NOVO: King of the North |
| Actually king of all of Europe. But looking at just the Nordic markets, Novo is doing all the work. Excluding Novo, the MSCI Nordic index remains stuck in an 18-month long bear market. |
 SEB X-Asset |
| Fat > handbags |
| It feels fundamentally sound that a company that cures obesity should be the highest valued one in Europe, rather than a company that sells overpriced handbags to people with low self-esteem. Novo Nordisk now worth >€400bn, LVMH ‘only’ €382bn. |
 Bloomberg |
| He wants to be the fattest cat… |
| Bernard Arnault has bought €215mln of LVMH shares since the luxury firm’s disappointing earnings in late July contributed to a drop in the stock price. Arnault’s fortune has fallen by $40bn since July. No longer the richest globally nor does he have the largest market cap in Europe. |
 Bloomberg |
| Huge! Americans will eat 30% less calories… |
| Lateral read-across! Morgan Stanley outlines how the biggest theme in healthcare now is making its way into the consumer. MS estimate a 20-30% reduction in daily calorie consumption as patients cut back on food intake across most categories and eat 20/40% fewer meals and snacks. Their proprietary US calorie model points to a 1-2% headwind to calories consumed by 2035 from the growing adoption of anti-obesity medications. (Morgan Stanley) |
